Antibodies clamp down on NET nucleosomes
In the current issue of CMI, Chirivi et al. describe the isolation and characterization of a monoclonal antibody that may find applications in numerous inflammatory conditions. This new antibody, called tACPA, inhibits the completion …
Landmark paper on Citryll’s NET inhibitor programme published in Nature’s Cellular and Molecular Immunology
Oss, The Netherlands, March 20, 2020 —www.citryll.com Citryll announced today that a landmark scientific paper has been published in Nature’s Cellular and Molecular Immunology journal, to be found at …
Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases
Excessive release of neutrophil extracellular traps (NETs) is associated with disease severity and contributes to tissue injury, followed
by severe organ damage …
Citryll moves to new premises at Pivot Park in Oss, The Netherlands
Oss, The Netherlands, October 21, 2019 —www.citryll.com Citryll announced today that it
has occupied new office and lab space at the Pivot Park in Oss the Netherlands.
Citryll collaborates with leading NET researcher Dr. Markus Hoffmann
Oss, The Netherlands, Erlangen, Germany September 18, 2019 —https://citryll.com/ announced today that it has established a collaboration with Dr. Markus Hoffmann of the Department of Medicine 3, Friedrich Alexander University of …
Citryll and Lonza Enter Into Partnership to Manufacture NETosis Inhibiting Antibody CIT-013
Oss, The Netherlands and Basel, Switzerland, 9 September 2019 – The Netherlands-based biotech Citryll and CDMO Lonza announced a partnership to develop and manufacture Citryll’s tACPA therapeutic antibody CIT-013.